SCHEMBL4093084

SCHEMBL4093084

CCNC(=O)Nc1cc(-c2cccc(N)c2C)nn2ccnc12

nearest known ligand 0.42

Predicted protein targets (top 5)

geneUniProtsupporting neighboursconfidence
SYK P43405 9/20 0.42
BTK Q06187 2/20 0.42
HDAC1 Q13547 1/20 0.39
FGFR1 P11362 1/20 0.35
SRC P12931 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4090599 0.89 SYK (0.44) SYKBTKHDAC1
SCHEMBL4093079 0.89 SYK (0.46) SYKBTK
SCHEMBL4096467 0.87 SYK (0.39) SYKBTKHDAC1
SCHEMBL13771582 0.83 BTK (0.52) SYKBTK
SCHEMBL2932606 0.82 BTK (0.63) BTK
SCHEMBL13771589 0.82 BTK (0.51) SYKBTK
SCHEMBL4080069 0.81 BTK (0.56) SYKBTK
SCHEMBL4084871 0.81 BTK (0.51) SYKBTK
SCHEMBL4080195 0.80 BTK (0.45) BTKHDAC1
SCHEMBL4090046 0.80 BTK (0.53) SYKBTK

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090186898-A1 Inhibitors of bruton's tyrosine kinase ROCHE PALO ALTO LLC 2009-07-23 US claimed
US-8426441-B2 Inhibitors of bruton's tyrosine kinase ROCHE PALO ALTO LLC (US) 2013-04-23 US disclosed
US-20090186898-A1 Inhibitors of bruton's tyrosine kinase ROCHE PALO ALTO LLC 2009-07-23 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090186898-A1 Inhibitors of bruton's tyrosine kinase BTK, SYK, LYN SYK 2/4885BTK 1/4885HDAC1 1180/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.